Cross-Phenotype GWAS Supports Shared Genetic Susceptibility to Systemic Sclerosis and Primary Biliary Cholangitis - Luo, Yiming; Khan, Atlas; Liu, Lili; Lee, Cue Hyunkyu; Perreault, Gabriel J; Pomenti, Sydney F; Gourh, Pravitt; Kiryluk, Krzysztof; Bernstein, Elana J (medRxiv, 2024)
Objective An increased risk of primary biliary cholangitis (PBC) has been reported in patients with systemic sclerosis (SSc). Our study aims to investigate the shared genetic susceptibility between the two disorders and to define candidate causal genes using cross-phenotype GWAS meta-analysis.Methods We performed cross-phenotype GWAS meta-analysis and colocalization analysis for SSc and PBC. We performed both genome-wide and locus-based analysis, including tissue and pathway enrichment analyses, fine-mapping, colocalization analyses with expression quantitative trait loci (eQTL) and protein quantitative trait loci (pQTL) datasets, and phenome-wide association studies (PheWAS). Finally, we used an integrative approach to prioritize candidate causal genes from the novel loci.Results We detected a strong genetic correlation between SSc and PBC (rg = 0.84, p = 1.7 × 10-6). In the cross-phenotype GWAS meta-analysis, we identified 44 non-HLA loci that reached genome-wide significance (p < 5 × 10-8). Evidence of shared causal variants between SSc and PBC was found for nine loci, five of which were novel. Integrating multiple sources of evidence, we prioritized CD40, ERAP1, PLD4, SPPL3, and CCDC113 as novel candidate causal genes. The CD40 risk locus colocalized with trans-pQTLs of multiple plasma proteins involved in B cell function.Conclusion Our study supports a strong shared genetic susceptibility between SSc and PBC. Through cross-phenotype analyses, we have prioritized several novel candidate causal genes and pathways for these disorders.What is already known on this topicSystemic sclerosis (SSc) and primary biliary cholangitis (PBC) are autoimmune disorders that exhibit overlapping clinical and histological features.The prevalence of PBC is higher in patients with SSc compared to the general population.Multiple susceptibility genomic loci have been identified for SSc and PBC through genome-wide association studies (GWAS).What this study addsThere is a strong genetic correlation between SSc and PBC, comparable in magnitude to the genetic correlation between SSc and systemic lupus erythematosus (SLE). This shared genetic susceptibility aligns with the observed increased relative risk of developing PBC and SLE in individuals with SSc.Using cross-phenotype GWAS and colocalization analysis, we have discovered nine genomic loci that account for the shared genetic etiology. Five of the nine loci were novel.Using an integrative approach, we have prioritized five novel candidate causal genes: CD40, ERAP1, PLD4, SPPL3 and CCDC113.The CD40 risk allele for SSc and PBC is paradoxically associated with reduced CD40 levels. Causal inference analyses indicate that this reduction in CD40 levels, due to CD40 locus polymorphism, leads to an increase in various plasma proteins involved in B cell activation, including the CD40 ligand.How this study might affect research, practice or policyMechanistic studies are needed to confirm the candidate causal genes prioritized by our in silico analyses.Our study advocates for heightened awareness among rheumatologists regarding the possibility of concurrent PBC in patients with SSc.Competing Interest StatementThe authors have declared no competing interest.Funding StatementDr. Luo was supported by the Rheumatology Research Foundation Scientist Development Award. Dr. Bernstein was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant K23-AR-075112), the National Heart, Lung, and Blood Institute (grant R01-HL-164758), and the Department of Defense (grant W81XWH2210163). Dr. Liu was supported by the National Institute of Diabetes and Digestive and Kidney Diseases (grant 1K01DK137031) Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Columbia University Institutional Review Board (AAAT8208, AAAC7385 and AAAV1102)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors